Nintedanib for Improving Reproductive Outcomes in Adenomyosis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Nintedanib, Progesterone.
- Who it may be relevant to
- Registry conditions: Adenomyosis of Uterus. Basic parameters: 20 years — 38 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Single-center, Randomized, Prospective, Controlled Clinical Study on the Efficacy of Nintedanib in Improving Reproductive Outcomes in Women With Adenomyosis
Overview
This study aims to evaluate the effectiveness and safety of nintedanib, an antifibrotic drug, in improving live birth rates for infertile women with adenomyosis who have frozen embryos. Based on promising animal data showing reduced uterine fibrosis, participants will be randomized to receive either standard progesterone therapy plus nintedanib or progesterone therapy alone for three months before undergoing a frozen embryo transfer cycle.
Interventions
- Drug Nintedanib
Participants will be randomly assigned to one of two groups: the Experimental Group will receive oral nintedanib (100 mg twice daily) plus progesterone therapy for three months; the Control Group will receive progesterone therapy only. - Drug Progesterone
For control group
Primary outcome measures
- live birth rate [Time frame: Up to approximately 9-12 months after embryo transfer (considering gestation)]
Eligibility criteria
Inclusion criteria
Aged 20-38, diagnosed with primary or secondary infertility; with at least one vitrified high-quality blastocyst (grading ≥4BB).
Diagnosed with adenomyosis within the last 3 months by MRI or transvaginal ultrasound, meeting the criteria of the Chinese Expert Consensus on Diagnosis and Treatment of Adenomyosis.
Body Mass Index (BMI) between 18-27 kg/m².
Regular menstrual cycles, no amenorrhea or severe dysfunctional uterine bleeding.
Normal ovarian reserve (AMH > 1 ng/mL or AFC ≥ 5 per ovary), not currently receiving ovarian suppression therapy.
Signed informed consent, able to understand and voluntarily participate, and willing not to participate in other clinical trials during the study period.
Exclusion criteria
Uterine or adnexal abnormalities (e.g., intrauterine adhesions, unicornuate/bicornuate/arcuate uterus, unremoved hydrosalpinx, endometrial polyp, submucosal myoma, or intramural myoma distorting the endometrial cavity).
History of GnRH agonist injection within 3 months prior to embryo transfer.
Unexplained abnormal vaginal bleeding.
Known active pelvic inflammatory disease.
Known genital malformation unsuitable for pregnancy.
Abnormal cervical cytology (TCT) results within 1 year before screening.
Severe impairment of liver or kidney function, heart disease, or hypertension.
Known history of thrombophlebitis or thromboembolic disease.
Any known clinically significant systemic disease (e.g., diabetes, tuberculosis).
Known history of recurrent miscarriage.
Chromosomal karyotype abnormality in either partner.
Either partner has a genetic disease deemed unsuitable for childbearing per the "Maternal and Infant Health Care Law".
Either partner has been exposed to teratogenic levels of radiation, toxins, or drugs.
Any condition/combined surgery/medication/other clinically significant abnormal lab finding judged by the investigator to potentially affect trial results.
Known refusal or inability to comply with the protocol requirements for any reason.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07162961 · New IVF